

RNS Number : 4718N
Redx Pharma plc
23 January 2023

REDX PHARMA PLC
("Redx" or "the Company")

Redx to Present at the 2nd Annual Wnt & β -Catenin Pathway Targeted Drug Development Summit

Alderley Park, UK, 23 January 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, announces that Dr. Simon Woodcock, Vice President, Oncology at Redx Pharma, will present at the 2nd Annual Wnt & β -Catenin Pathway Targeted Drug Development Summit (24 - 26 January, Boston, MA).

In the presentation, which will take place on Thursday 26 January at 10:30 (EST), Dr. Woodcock will discuss the challenges of genetic selection in defined patient populations and how this relates directly to Wnt/ β -Catenin Biomarkers in patient selection for clinical studies of targeted therapies, such as Redx's RXC004.

RXC004 is a clinical stage, highly potent and selective, orally active Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand dependent cancer. It is currently being evaluated in Phase 2 proof-of-concept clinical studies as a monotherapy and in combination with anti-PD-1, Nivolumab, in genetically selected metastatic colorectal cancer (MSS mCRC) ([clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04907539) NCT04907539), as monotherapy in genetically selected pancreatic cancer, and as a monotherapy and in combination with anti-PD-1, Pembrolizumab, in biliary tract cancers ([clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04907851) NCT04907851).

Details of the presentation are as follows:

Title: Leveraging Wnt/ β -Catenin Biomarkers for Patient Selection for Targeted & Precision Therapies
Day/Date: Thursday, 26 January 2023
Time: 10:30 EST

A copy of the presentation will be made available on the Company's website following the presentation at: <https://www.redxpharma.com/scientific-publications/>

For further information, please contact:

Redx Pharma Plc T: +44 (0)1625 469 918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com

Lisa Anson, Chief Executive Officer

US Office
Peter Collum, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550
Matt Davis/ Adam Dawes

WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330
Claes Spång/ Satheesh Nadarajah/ David Wilson

Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500
Rupert Dearden/ Freddy Crossley/ Emma Earl

FTI Consulting

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at the end of 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFLFFDLLIFFIV